Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer
Status:
Unknown status
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This study is to compare the effective of Paclitaxel combined with Epirubicin and Paclitaxel
plus Carboplatin in the neoadjuvant treatment for TNBC. And the investigators hypothesized
that paclitaxel combined with carboplatin is more sensitive to TNBC compared with Paclitaxel
plus Epirubicin,this study will also have a look into the relation of BRCA1 mutation and
sensitive to carboplatin.